

Research Article

Antioxidant and Antiproliferative Potential of Bioactive Molecules Ursolic Acid and Thujone Isolated from *Memecylon edule* and *Elaeagnus indica* and Their Inhibitory Effect on Topoisomerase II by Molecular Docking Approach

Ramalingam Srinivasan,^{1,2,3} Arumugam Aruna,² Jong Suk Lee,⁴ Myunghye Kim ¹,
Muthugounder Subramaniam Shivakumar,³ and Devarajan Natarajan ³

¹Department of Food Science and Technology, Yeungnam University, Gyeongsan-si, Gyeongsangbuk-do 38541, Republic of Korea

²Department of Biotechnology, K. S. Rangasamy College of Arts and Science, K. S. R. Kalvi Nagar, Tiruchengode 637215, Namakkal, Tamil Nadu, India

³Department of Biotechnology, Periyar University, Salem 636 011, Tamil Nadu, India

⁴Department of Food & Nutrition & Cook, Taegu Science University, Daegu 41453, Republic of Korea

Correspondence should be addressed to Myunghye Kim; foodtech@ynu.ac.kr and Devarajan Natarajan; natarajpu@gmail.com

Received 29 August 2019; Revised 11 December 2019; Accepted 4 January 2020; Published 14 February 2020

Guest Editor: Yearul Kabir

Copyright © 2020 Ramalingam Srinivasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study aimed to evaluate the antioxidant and antiproliferative potential of ursolic acid and thujone isolated from leaves of *Elaeagnus indica* and *Memecylon edule* and their inhibitory effect on topoisomerase II using molecular docking study. The isolated ursolic acid and thujone were examined for different types of free radicals scavenging activity, the antiproliferative potential on U-937 and HT-60 cell lines by adopting standard methods. Further, these compounds were docked with the active site of the ATPase region of topoisomerase II. The findings of the research revealed that ursolic acid harbor strong antioxidant and antiproliferative capacity with low IC₅₀ values than the thujone in all tested methods. Moreover, ursolic acid shows significant inhibition effect on topoisomerase II with a considerable docking score (−8.0312) and GLIDE energy (−51.86 kca/mol). The present outcome concludes that ursolic acid possesses significant antioxidant and antiproliferative potential, which can be used in the development of novel antioxidant and antiproliferative agents in the future.

1. Introduction

Free radicals are involved in numerous cellular functions including defense mechanisms and cell signaling and are essential for the aerobic metabolism. However, the overproduction of free radicals in cells leads to oxidative stress, consequently causing damage to vital macromolecules, like DNA, lipids, and proteins [1]. Several degenerative related diseases such as cancer, inflammation, atherosclerosis, cataracts, asthma, diabetes mellitus anemia, brain dysfunction, arthritis, liver diseases, and renal problems are predominantly linked to the oxidative stress [2].

Cancer is the malignant illness and the second most leading cause of mortality worldwide. Globally, various types of cancer caused 9.6 million deaths in 2018, approximately 1 in 6 deaths. The people of low- and middle-income countries are highly affected by cancer, due to the change in behavior and diet, and the estimates were around 70% of deaths [3]. In western countries, hormone-dependent cancers such as breast, prostate, and uterine cervix are a common cause of several deaths [4]. Nowadays, different treatments such as chemotherapy, surgery, radiotherapy, and antihormone therapy are used to treat cancer. However, these therapies are expensive and cause an adverse effect on host health. Several

plant-derived compounds like vinblastine, vincristine, taxol, and camptothecin were used in the treatment of cancer [5]. Thus, various research groups around the world have focused on the investigation of plant extract to find a plant-based novel, broad-spectrum, cost-effective, better, and safer anticancer and antioxidant agent from plant materials [6].

Elaeagnus indica (Elaeagnaceae) and *Memecylon edule* (Melastomataceae) are known to possess various ethnobotanical properties and used to treat various ailments in traditional medicine [2, 7, 8]. Both plants were reported to have various biological activities, including larvicidal, antibacterial, anti-inflammatory, analgesic, antioxidant, and anticancer activities, and few compounds were identified [1, 2, 7–17]. However, there is no data available on the antioxidant and antiproliferative properties of the isolated compound thujone (from *Elaeagnus indica*). Even though anticancer and antiproliferative activity of ursolic acid (isolated from *Memecylon edule*) were reported [18–21], there is no data available on growth inhibitory effect of ursolic acid on the human leukemic monocyte lymphoma (U-937) cells, and antioxidant potential of ursolic acid was the least explored. Moreover, there are no previous studies available on the *in silico* inhibition interactions of thujone and ursolic acid with topoisomerase II in detail. Thus, the present investigation aimed to examine the antioxidant and antiproliferative potential of ursolic acid and thujone isolated from leaves of *Elaeagnus indica* and *Memecylon edule* and evaluate their inhibitory effect on the topoisomerase II using molecular docking tools.

2. Materials and Methods

2.1. Plant Materials. Fresh and healthy aerial parts of *Elaeagnus indica* and *Memecylon edule* were collected from different regions of Shervarayan Hills (latitude 11°47'–12°33' N, longitude 77°02'–78°40' E, 1300–400 m MSL), Salem District, and Kolli Hills (latitude 10°12'–11°07' N, longitude 76°–77°17' E, 900–1100 m MSL), Namakkal District, Tamil Nadu, India, respectively. The nomenclature of collected plant material was authenticated by the Botanical Survey of India (BSI) (*E. indica* reference letter No. BSI/SRC/5/23/2014–15/Tech/1942 and *M. edule* reference letter No. BSI/SRC/5/23/2014–15/Tech./248) Coimbatore, Tamil Nadu, India. Herbarium specimens of collected plants were deposited (*E. indica* specimen No. PU/DBT/NDRL//2010/03 and *M. edule* specimen No. PU/DBT/NDRL//2010/05) in Natural Drug Research Laboratory (NDRL), Department of Biotechnology, Periyar University, Salem, Tamil Nadu, India. The plant materials were washed with the running water prior to sterile distilled water and air-dried at room temperature for 14–21 days. The dried plant materials were pulverized, using an electric grinder, and then sieved through 100-mesh sifter and stored in an airtight container for further use.

2.2. Extraction of Plant Materials. Pulverized plant materials (2 kg) were successively extracted with various organic solvents such as hexane, chloroform, ethyl acetate, acetone,

and methanol (1 : 5 solvent ratio) in an increasing polarity manner using a Soxhlet apparatus until the efflux solvents become colorless. The extracts were filtered through Whatman No. 1 filter paper and condensed using a rotary evaporator in vacuum at 40°C which yields greenish crude extracts. These extracts were stored in an airtight container at 4°C until use.

2.3. Isolation of Bioactive Molecules. Based on the preliminary results of phytochemical profile and biological activity [7, 8, 14–17], two extracts (namely acetone extract of *E. indica* and the ethyl acetate extract of *M. edule*) were selected for the isolation of active principles. The activity guided isolation of extract yields two active compounds [15, 17]. These compounds were identified using various spectral studies, like UV, FT-IR, LCMS, ¹H, ¹³C, DEPT-135, HMBC, and HSQC Nuclear Magnetic Resonance [15, 17].

2.4. In Vitro Antioxidant Studies. Antioxidant potential of isolated compounds were examined on different types of free radicals, that is, DPPH, nitric oxide, hydroxyl, and superoxide radical and ferric reducing antioxidant power assay (FRAP) as per the previous standard methods [22–25]. Various concentrations (20–100 µg/mL) of the isolated compounds were used in the radical scavenging potential analysis. Similar concentrations of a natural (ascorbic acid) and synthetic compound butylated hydroxyanisole (BHA) were used as reference molecules in all antioxidant investigations.

2.5. Antiproliferative Activity. The human leukemic monocyte lymphoma (U-937) and human acute promyelocytic leukemia (HT-60) cell lines were acquired from the National Institute of Cell Sciences, Pune, India, and maintained in Minimal Essential Medium (MEM) supplemented with 10% (v/v) heat-inactivated Fetal Bovine Serum (FBS), 3% L-glutamine, 100 IU/mL penicillin G, and 100 µg/mL streptomycin in a 5% CO₂ incubator at 37°C. The antiproliferative potential of isolated compounds was detected by methyl thiazolyl diphenyl-tetrazolium bromide (MTT) by adopting the method of Srinivasan et al. [16] on U-937 and HT-60 cell lines.

2.6. Molecular Docking Studies. Molecular interactions of ursolic acid and thujone with topoisomerase II (PDB id: 1QZR) were studied using *GLIDE* (*Grid-Based Ligand Docking with Energetics*) [26] software v5.5 developed by Schrödinger executed on Red Hat Enterprise Linux 5. *Maestro* v9.0 used for the preparation of ligands and proteins and docking study was carried out in Graphical User Interface (GUI, *Maestro*, 2009) workspace. *LigPrep* (Schrödinger suite, 2009) module of v2.3 of Schrödinger Suite 2009 was used to prepare the ligands. The energy minimization of *LigPrep* follows the optimized potential liquid simulations for all-atom force fields. Induced fit docking (IFD) of the prepared ligands with target proteins was done in *Induced Fit Docking* protocol of *GLIDE* v5.5

TABLE 1: DPPH radical scavenging activity of ursolic acid and thujone.

Concentration ($\mu\text{g/mL}$)	DPPH radical scavenging activity (% of inhibition)*			
	Ursolic acid	Thujone	Ascorbic acid	BHA
20	11.92 ± 0.53^a	19.00 ± 0.33^a	53.22 ± 0.27^a	65.42 ± 0.44^a
40	37.33 ± 0.57^b	31.51 ± 0.64^b	61.12 ± 0.66^b	69.77 ± 0.58^b
60	41.36 ± 0.31^c	49.05 ± 0.62^c	73.68 ± 0.38^c	74.08 ± 0.38^c
80	55.96 ± 0.54^d	63.25 ± 0.82^d	79.80 ± 0.27^d	79.94 ± 0.17^d
100	76.92 ± 0.53^e	72.79 ± 0.82^e	83.53 ± 0.41^e	84.73 ± 0.38^e

*The values are mean of triplicates with (\pm) standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a–e) in column within treatments indicates significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test.

(Schrödinger Suite 2009). The images of docked complexes and hydrogen bond interactions were analyzed in the *PyMol* Molecular Graphics System. *Ligplot* diagram of docked complexes was obtained from PDBsum server (<http://www.ebi.ac.uk/pdbsum>) for better clarity.

2.6.1. Preparation of Topoisomerase II. The crystal structure of the 1QZR complex (ATPase region of topoisomerase II from *Saccharomyces cerevisiae*) was retrieved from PDB which contains two identical 418 amino acid length polypeptide chains (A and B) with one (s)-4, 4'-(1-methyl-1,2-ethanediy) bis-2,6-piperazinedione (CDX), phosphoaminophosphonic acid-adenylate ester (ANP), and magnesium ion in each chain. Two methods were used in the preparation of protein for docking study. In the first method, all the water molecules, one CDX, one magnesium ion, and one ANP were removed and in the second method the the water molecules present in 1QZR were removed.

2.7. Statistical Analyses. All the analyses used in the present research were carried out in triplicate. Data were represented as the mean \pm standard deviation of three quotients. The inhibitory concentrations 50 (IC_{50}) were calculated by the curve fitted method using OriginPro 8 software. The significant difference was obtained from the results of Tukey's test ($p < 0.05$) of ANOVA (SPSS 25.0).

3. Results and Discussion

3β -hydroxyurs-12-en-28-oic acid (ursolic acid, a pentacyclic triterpenoid) and 1-isopropyl-4-methylbicyclo [3.1.0] hexan-3-one (thujone, a monoterpene ketone) were isolated from *Memecylon edule* and *Elaeagnus indica*, respectively, through activity guided isolation methods. Those compounds' isolation and structural elucidation were reported [15, 17]. Previously, these isolated compounds were reported from different parts of several plants [15–18].

3.1. In Vitro Antioxidant Studies. Both the isolated compounds ursolic acid and thujone expressed good to moderate radical scavenging activity in all tested methods in a concentration-dependent manner (Tables 1–5). Ursolic acid exhibited significant free radical scavenging activity on all tested radicals with the lowest $\text{IC}_{50}/\text{EC}_{50}$ values followed by thujone with sustainable IC_{50} values. Ursolic acid expressed good Fe^{3+} reduction potential in FRAP assay with the least

EC_{50} value $18.42 \pm 0.03 \mu\text{g/mL}$ (Table 2) followed by hydroxyl radicals (IC_{50} value $29.69 \pm 0.44 \mu\text{g/mL}$) (Table 3). NO radical scavenging potential of ursolic acid and thujone is almost similar to high IC_{50} value of $70.40 \pm 0.88 \mu\text{g/mL}$ and $77.68 \pm 0.58 \mu\text{g/mL}$, respectively, which are 2-fold higher than the positive control ascorbic acid (Table 4). Both the ursolic acid (76.92 %) and thujone (72.79 %) show nearly similar percentage of DPPH radical scavenging potential. However, considerable difference was found in the IC_{50} values (Table 1). Ursolic acid expressed a significantly high superoxide radical scavenging ability with low IC_{50} value of $43.35 \pm 0.95 \mu\text{g/mL}$, which is lower than both natural and synthetic antioxidant controls, namely, ascorbic acid and BHA, respectively (Table 5). Thujone show the lowest quenching ability on the superoxide radicals with high IC_{50} value of $131.78 \pm 1.27 \mu\text{g/mL}$ (Table 6). The results of the antioxidant potential of thujone revealed that IC_{50} values of all radical scavenging activity were two- to threefold higher than the isolated ursolic acid when compared with reference compounds in most of the tested methods. Maximum antiradical activity was found in FRAP method with of EC_{50} value of $44.58 \pm 0.89 \mu\text{g/mL}$. The results of the rest of assays expressed considerable radical scavenging potential of thujone.

The present investigation used 5 different assays to assess the antioxidant potential of ursolic acid and thujone. Both ursolic acid and thujone expressed different degree of radical scavenging potential on various tested radicals. The difference in the antioxidant capacity of the tested compounds obtained by the results of FRAP, DPPH radical, hydroxyl radical, nitric oxide radical, and superoxide radical scavenging methods is probably a result of the variation in sensitivity of isolated compounds to the various species of radicals [27]. Moreover, the variation in the reaction media such as lipophilic, hydrophilic, and amphiphilic and nature of radicals and antioxidant molecules have impact on the antiradical potential. For example, DPPH radicals are used to evaluate the antiradical potential of both hydrophilic and hydrophobic antioxidants, whereas nitric oxide assay is used for hydrophilic antioxidants [27]. The difference in the antioxidant potential of ursolic acid and thujone is due to the variation in their structure and functional groups such as free hydroxyl moiety and polarity.

There are no studies/reports on the antioxidant activity of thujone. However, several reports are present on the antioxidant activity of essential oils from various plants, that is, *Salvia officinalis* [28], *Artemisia herba-alba* [29],

TABLE 2: FRAP activity of ursolic acid and thujone.

Concentration ($\mu\text{g/mL}$)	FRAP (OD values)*			
	Ursolic acid	Thujone	Ascorbic acid	BHA
20	0.543 ± 0.006^a	0.084 ± 0.016^a	0.305 ± 0.007^a	0.885 ± 0.007^a
40	0.827 ± 0.006^b	0.366 ± 0.009^b	0.593 ± 0.006^b	1.360 ± 0.006^b
60	1.037 ± 0.006^c	0.923 ± 0.023^c	0.988 ± 0.010^c	2.133 ± 0.011^c
80	1.357 ± 0.006^d	1.078 ± 0.015^d	1.505 ± 0.040^d	2.510 ± 0.009^d
100	1.427 ± 0.170^d	1.451 ± 0.005^e	2.134 ± 0.012^e	2.993 ± 0.005^e

*The values are mean of triplicates with (\pm) standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a-e) in column within treatments indicate significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test.

TABLE 3: Hydroxyl radical scavenging activity of ursolic acid and thujone.

Concentration ($\mu\text{g/mL}$)	Hydroxyl radical scavenging activity (% of inhibition)*			
	Ursolic acid	Thujone	Ascorbic acid	BHA
20	46.59 ± 0.24^a	26.43 ± 0.51^a	49.60 ± 0.55^a	42.75 ± 0.52^a
40	53.48 ± 0.07^b	47.02 ± 0.71^b	61.40 ± 0.41^b	49.65 ± 0.38^b
60	60.20 ± 0.33^c	53.35 ± 0.47^c	76.43 ± 0.34^c	60.18 ± 0.75^c
80	70.51 ± 0.21^d	56.76 ± 0.30^d	88.25 ± 0.42^d	73.15 ± 0.38^d
100	74.62 ± 0.17^e	63.34 ± 0.22^e	94.06 ± 0.60^e	88.55 ± 0.57^e

*The values are mean of triplicates with (\pm) standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a-e) in column within treatments indicates significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test.

TABLE 4: Nitric oxide radical scavenging activity of ursolic acid and thujone.

Concentration ($\mu\text{g/mL}$)	Nitric oxide radical scavenging activity (% of inhibition)*			
	Ursolic acid	Thujone	Ascorbic acid	BHA
20	21.70 ± 0.25^a	14.25 ± 0.88^a	28.80 ± 1.21^a	30.26 ± 0.66^a
40	32.86 ± 0.32^b	29.61 ± 0.66^b	54.53 ± 0.91^b	41.23 ± 1.54^b
60	40.16 ± 0.34^c	39.55 ± 2.16^c	65.79 ± 0.96^c	53.58 ± 0.67^c
80	59.49 ± 0.18^d	51.24 ± 0.51^d	79.39 ± 1.22^d	65.35 ± 1.54^d
100	70.50 ± 0.39^e	74.12 ± 0.66^e	94.15 ± 1.13^e	87.28 ± 0.38^e

*The values are mean of triplicates with (\pm) standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a-e) in column within treatments indicates significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test.

TABLE 5: Superoxide radical scavenging activity of ursolic acid and thujone.

Concentration ($\mu\text{g/mL}$)	Superoxide radical scavenging activity (% of inhibition)*			
	Ursolic acid	Thujone	Ascorbic acid	BHA
20	24.11 ± 1.13^a	07.95 ± 0.71^a	25.31 ± 0.29^a	13.04 ± 0.62^a
40	48.49 ± 0.41^b	$10.95 \pm 0.37^{a,b}$	34.24 ± 0.42^b	24.10 ± 0.45^b
60	57.71 ± 0.89^c	$19.82 \pm 0.58^{a,b}$	44.62 ± 0.54^c	37.28 ± 0.17^c
80	64.67 ± 0.41^d	24.64 ± 0.37^b	60.06 ± 0.50^d	40.18 ± 0.42^d
100	76.91 ± 0.33^e	43.41 ± 9.69^c	75.56 ± 0.25^e	56.35 ± 0.29^e

*The values are mean of triplicates with standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a-e) in column within treatments indicates significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test.

TABLE 6: Antioxidant activities IC_{50}/EC_{50} values of ursolic acid and thujone.

Assays	IC_{50}/EC_{50} values ($\mu\text{g/mL}$)#			
	Ursolic acid	Thujone	Ascorbic acid	BHA
DPPH radical	71.86 ± 0.54	60.92 ± 1.61	18.77 ± 0.52	15.48 ± 0.61
FRAP	18.42 ± 0.03	44.58 ± 0.89	33.62 ± 0.61	11.24 ± 0.37
Hydroxyl radical	29.69 ± 0.44	49.47 ± 0.62	20.47 ± 0.86	40.78 ± 0.98
Nitric oxide radical	70.40 ± 0.08	77.68 ± 0.58	36.43 ± 0.71	53.90 ± 0.64
Superoxide radical	43.35 ± 0.95	131.78 ± 1.27	67.03 ± 0.80	90.84 ± 1.76

#The values are mean of triplicates with standard deviation (mean \pm S.D; $n = 3$).

TABLE 7: Antiproliferative activity of ursolic acid and thujone on U-937 and HL-60 cell lines.

Concentration ($\mu\text{mol/mL}$)	% Cell viability*			
	Ursolic acid		Thujone	
	U-937 CL [#]	HL-60 CL [#]	U-937 CL [#]	HL-60 CL [#]
03.13	73.15 \pm 2.01 ^h	69.64 \pm 0.68 ^h	90.17 \pm 1.08 ^h	96.33 \pm 0.78 ^h
06.25	65.18 \pm 1.86 ^g	66.92 \pm 1.31 ^h	85.80 \pm 0.64 ^g	88.88 \pm 0.91 ^g
12.50	59.63 \pm 0.67 ^f	56.29 \pm 0.75 ^g	78.38 \pm 1.64 ^f	83.22 \pm 1.10 ^f
25.00	54.69 \pm 0.64 ^e	50.44 \pm 0.79 ^f	71.38 \pm 1.03 ^e	77.48 \pm 1.66 ^e
50.00	44.66 \pm 1.35 ^d	45.18 \pm 0.75 ^e	69.67 \pm 0.68 ^e	71.15 \pm 1.23 ^d
100.0	32.74 \pm 2.58 ^c	39.01 \pm 1.17 ^d	64.59 \pm 1.20 ^d	56.22 \pm 0.70 ^c
250.0	27.67 \pm 1.28 ^b	33.37 \pm 1.17 ^c	53.85 \pm 1.80 ^c	52.66 \pm 1.52 ^b
500.0	23.08 \pm 1.65 ^a	29.15 \pm 0.55 ^b	42.51 \pm 0.73 ^b	49.67 \pm 0.69 ^b
1000	19.67 \pm 0.98 ^a	23.70 \pm 1.27 ^a	37.29 \pm 1.43 ^a	44.66 \pm 1.26 ^a

Control, nil mortality. *The values are mean of triplicates with standard deviation (mean \pm S.D; $n = 3$). Different superscript letters (a-i) in column within treatments indicates significant differences (at $p < 0.05$) when subject to Tukey's multiple comparison test, CL[#], cell line.

Artemisia japonica, *Artemisia nilagirica* [30], and *Artemisia absinthium* [31], which contains high amount of thujone. Based on the results of the aforementioned studies, thujone exhibited low to moderate antioxidant activities of all tested radicals. Mighri et al. [32] reported that thujone-rich oil from *Artemisia herba-alba* showed the lower inhibition percentage of antioxidant activity than the positive control (BHA) which strengthens the outcome of the present study. Earlier study on the antioxidant potential of ursolic acid shows similar IC₅₀ value for the DPPH radicals scavenging activity [33] which supports the findings of the present investigation.

3.2. Antiproliferative Activity. The results of the antiproliferative activity of ursolic acid and thujone expressed notable growth inhibitory effect on both U937 and HL-60 cells in a dose-dependent manner (Table 7). The present study shows ursolic acid harbor higher antiproliferative potential on both U-937 and HL-60 cells than the thujone. Furthermore, the findings of the present investigation revealed that HL-60 cells were more sensitive to ursolic acid than U-937 cells (Figure 1). Ursolic acid possessed a profound inhibitory effect on the proliferation of HL-60 cells (~77% growth inhibition) with the lowest IC₅₀ value (26.83 \pm 3.07 $\mu\text{mol/mL}$) followed by U-937 cells (~80% growth inhibition) with considerable IC₅₀ value (36.59 \pm 0.80 $\mu\text{mol/mL}$). Thujone shows moderate antiproliferative potential on U-937 cells (~63% growth inhibition) with a high IC₅₀ value of 297.42 \pm 1.64 $\mu\text{mol/mL}$ (Figure 2). The least cytotoxic activity on HL-60 cell line (~56% growth inhibition) with a higher IC₅₀ value of 486.15 \pm 2.74 $\mu\text{mol/mL}$ was noticed in thujone.

The total number of U937 and HL-60 cells was decreased with increased dose of both ursolic acid and thujone. Distinctive morphological changes in the U937 and HL-60 cells occurred with increasing concentration of ursolic acid and thujone treatment (Figures 1 and 2). Typical apoptotic features such as cell shrinkage and membrane blebbing were found in the U937 and HL-60 cells upon the low- to mid-and/or high-dose treatment of ursolic acid and thujone [27]. The treatment of ursolic acid and thujone induced the loss of cellular adhesion, echinoid spikes, and blistering. Moreover,

the cells are detached from their basal membrane (anoikis) and lost their contact with adjacent cells upon treatment of ursolic acid and thujone at high dose. The increasing concentration of ursolic acid and thujone induced cell death through the necrosis process which, detected with characteristic morphological changes of necrosis in U937 and HL-60 cells such as membrane bubbling, detached from neighbor cells and evaginations [28]. Similarly, morphological changes were reported in the ursolic acid-treated various cancer cells that support the present findings [18–20, 33–36].

Ursolic acid is reported to have antiproliferative activity on different types of cancers such as lung, colon, breast, renal, prostate, melanoma, and leukemia [18–20, 33–36]. Many reports support the antiproliferative potential of ursolic acid because it might induce the apoptosis process in different mode on various types of cell lines [37, 38]. Previously, the antiproliferative activity of ursolic acid on HL-60 cell line was well-reported. It mainly induced apoptosis in HL-60 leukemia cells accompanied by mediating the release of intracellular calcium ions [39], inhibiting DNA synthesis [40] and blocking the cell cycle process [39, 41], and inducing Atg5-dependent autophagy [42] and mitochondria dependent apoptosis [19] which supports the findings of the present study. Moreover, many reviews described the mode of action of ursolic acid in the control of cancer cells [18–21].

Biswas et al. [43] evaluated the antiproliferative and apoptosis-inducing properties of thujone-rich fraction separated from *Thuja occidentalis* on melanoma (A375) cell line harbor higher IC₅₀ (226.18 $\mu\text{g/mL}$) value. Moreover, the thujone-rich fraction displayed least (~14%) cytotoxicity on normal peripheral blood mononuclear cell (PBMC) [44] (Biswas et al., 2010). Similarly, Zolotovich et al. [44] reported that thujone exhibits no cytotoxic effect on HeLa cells at high concentrations (100 $\mu\text{g/mL}$), which supports the outcome of present study. Likewise, Privitera et al. [5] documented that thujone-rich essential oil from *Salvia officinalis* has no cytotoxic effect on the LNCaP cells in all tested concentrations that strengthen the present findings.

3.3. Molecular Docking Studies. DNA topoisomerases are ubiquitous enzymes that unwind DNA molecule which is




FIGURE 1: Antiproliferative potential (a and b) of isolated thujone (1-normal cells, 2-cell shrinkage, 3-membrane blebbing, 4-echinoid spikes, and 5-anoikis). (a) Antiproliferative effect of isolated thujone on U-937 cell line. (b) Antiproliferative effect of isolated ursolic acid on HL-60 cell line.




FIGURE 2: Antiproliferative potential (a and b) of isolated ursolic acid (1-normal cells, 2-cell shrinkage, 3-membrane blebbing, and 4-echinoid spikes). (a) Antiproliferative effect of isolated ursolic acid on U-937 cell line. (b) Antiproliferative effect of isolated ursolic acid on HL-60 cell line.

necessary for various DNA dependent biological processes [45]. Generally, two types of topoisomerases are predominantly found in cells, namely, type I and type II. Type I

topoisomerases break single strand of duplex DNA that create a gate for the transition of the another DNA strand, whereas type II topoisomerases cut the double strands of

TABLE 8: Docking results of ursolic acid and thujone with topoisomerase II (1QZR).

Compounds	Docking score	GLIDE energy (kcal/mol)	Interactions D-H...A	D...A* distance (Å)
<i>Target protein: 1QZR (single chain)</i>				
Ursolic acid	-4.2933	-37.82	(O-H...O) ASN142 PHE362 (N-H...O) (O-H...O) THR27 GLN365 (N-H...O)	2.79 2.93 2.85 2.98
Thujone	-5.4444	-16.964	TYR28 (O-H...O) GLN365 (N-H...N) (O-H...O) THR363 (N-H...O) THR363	3.05 3.15 3.30 3.16
CDX (cocrystallized ligand)	-7.0166	-35.33	(N-H...O) PHE362 (O-H...O) PHE362 PHE362 (N-H...O)	3.32 2.80 3.46
<i>Target protein: 1QZR (double chain)</i>				
Ursolic acid	-8.0312	-51.86	(N-H...O) ARG77A THR195B (O-H...O) TYR144A (O-H...O)	3.36 2.86 2.94
Thujone	-8.1810	-27.38	TYR28B (O-H...O) (O-H...O) THR27A GLN365A (O-H...N)	2.93 3.24 2.74
CDX (cocrystallized ligand)	-12.105	-56.86	GLN365A (O-H...N)	2.73

*D, donor; A, acceptor.

DNA and transit another duplex DNA through the gate and then both type I and type II topoisomerases religate the broken DNA strands [45]. Both the type I and type II topoisomerases are involved in the maintenance of the DNA topology. Inhibition of either type I or type II has significant impact on the DNA replication and other biological process. Expression level of topoisomerase II is often elevated in cancer cells [46]. Therefore, topoisomerase II is an attractive target for various antitumor and antimicrobial drugs [47]. The clinically successful/approved anticancer drugs which target the topoisomerase II induce topoisomerase II poisoning that leads to the arrest of replication and formation of duplex DNA break as the result cells undergo apoptosis [46]. Previous studies revealed that terpenes and terpenoids are potential inhibitor of topoisomerase II [47, 48] and they prefer to bind at the ATPase domain due to the hydrophobic nature of binding site [49]. Ursolic acid and thujone are lipophilic in nature. Thus, in the present study, topoisomerase II ATPase region was selected as a target.

Ursolic acid and thujone possess a significant binding affinity with topoisomerase II. The H-bond interactions between the ligands and proteins are N-H...O and O-H...O type. Besides the H-bond interactions, van der Waals and hydrophobic interactions with the ATPase region residues of topoisomerase II were noticed. The results of ursolic acid and thujone were compared with the docked pattern of CDX (cocrystallized ligand). The GLIDE energy of ligands, H-bond interactions along with distance, and docking score are given in Table 8. Ursolic acid showed H-bond interactions with the active site Thr27, Asn142, and Phe362 residues of a single chain of topoisomerase II (Figure 3) along with other nonbonded interactions with a sustainable docking score (-4.29) and GLIDE energy (-37.82 kcal/mol).




FIGURE 3: Binding of thujone at the interface of topoisomerase II (chain A) and the corresponding interactions with the residues.

Moreover, while ursolic acid docked with both A and B chains displayed H-bond interactions with the Arg77a and Thr195b residues with notable GLIDE energy (-51.86 kcal/mol) and docking score (-8.0312) (Figure 4), thujone expressed H-bond interaction with the Gln365 residue (Figure 5) when docked with a single chain of topoisomerase II along with hydrophobic interactions with a docking score of -5.44 and GLIDE energy -16.96 kcal/mol. While docking, the thujone with two chains of topoisomerase II displayed interactions with Tyr144a and Tyr28b residues (Figure 6) with a considerable docking score (-8.18) and GLIDE energy (-27.38 kcal/mol). The docking results clearly show that ursolic acid is a strong inhibitor of 1QZR and energetically similar to the CDX. Hence, the anti-proliferative activity of ursolic acid might be persistent via the findings of molecular docking studies with respect to the inhibition of topoisomerase II.




FIGURE 4: Binding of thujone at the interface of topoisomerase II (double chain) and the corresponding interactions with the residues.




FIGURE 5: The interactions exhibited by ursolic acid with the active residues of topoisomerase II (chain A) and the corresponding interactions with the residues.

There are no detailed data available on the docking studies of ursolic acid and thujone with topoisomerase II. Even though earlier reports revealed that ursolic acid has significant inhibition potential on topoisomerase II in *in vitro* and *in vivo* assays [50], no detailed data is available on their *in silico* interactions. Two docking studies report the binding energy of ursolic acid (used as control) with topoisomerase II ATPase site (1QZR) but do not show

the interaction between them. Those studies reported -21.2 kcal/mol [48] and -57.7 kJ/mol [51] (equivalent to -13.79 kcal/mol) as a binding energy of ursolic acid with topoisomerase II which is 2.44- and 3.76-fold higher than the present study, respectively; and the possible reason for the difference in binding energy is variations in the protein preparation and docking platform. This is the firsthand report of the *in silico* interactions of ursolic acid and thujone




FIGURE 6: The binding of ursolic acid at the interface of topoisomerase II (double chain) and the corresponding interactions with the residues.

at the ATPase region of topoisomerase II. The anti-proliferative activity of ursolic acid is supported by the docking results which may be achieved due to the inhibition of topoisomerase II.

4. Conclusion

Overall outcome of this investigation concludes that ursolic acid isolated from *M. edule* harbors significant antioxidant and antiproliferative potential with low IC_{50} values than the thujone isolated from *E. indica*. HL-60 cells are more sensitive to ursolic acid than the U-936 cells. The outcome of docking results shows that the ursolic acid has a strong affinity with the ATPase active site of topoisomerase II. Ursolic acid might be used as a good molecular template in the discovery of novel and highly potent antioxidant and antiproliferative agents.

Data Availability

No data were used to support this study.

Disclosure

R. Srinivasan, A. Aruna, M. S. Shivakumar, and Jong Suk Lee are co-first authors.

Conflicts of Interest

The authors declare that they do not have any conflicts of interest.

Acknowledgments

This work was supported by the University Grants Commission (UGC), New Delhi (Ref. no. 37-296/2009 (SR)), and the authors from Periyar University, acknowledged DST-

FIST (SR/FIST/LSI-673/2016) for release major grant to the Department of Biotechnology, for strengthening the instrumentation facility.

References

- [1] R. Srinivasan, A. Aruna, K. Manigandan et al., "Phytochemical, antioxidant, antimicrobial and antiproliferative potential of *Elaeagnus indica*," *Biocatalysis and Agricultural Biotechnology*, vol. 20, Article ID 101265, 2019.
- [2] R. Srinivasan, D. Natarajan, and M. S. Shivakumar, "Antioxidant compound Quercetin-3-O- α -L-rhamnoside(1 \rightarrow 6)- β -D-glucose (Rutin) isolated from ethyl acetate leaf extracts of *mecycylon edule* Roxb (Melastamataceae)," *Free Radicals and Antioxidants*, vol. 5, no. 1, pp. 35–42, 2015.
- [3] WHO, *WHO Cancer Report 2018*, International Agency for Research on Cancer, Lyon, France, 2018, <https://www.who.int/news-room/fact-sheets/detail/cancer>.
- [4] M. S. Sierra, I. Soerjomataram, S. Antoni et al., "Cancer patterns and trends in Central and South America," *Cancer Epidemiology*, vol. 44, no. 1, pp. S23–S42, 2016.
- [5] G. Privitera, T. Luca, S. Castorina, R. Passanisi, G. Ruberto, and E. Napoli, "Anticancer activity of *Salvia officinalis* essential oil and its principal constituents against hormone-dependent tumour cells," *Asian Pacific Journal of Tropical Biomedicine*, vol. 9, no. 1, pp. 24–28, 2019.
- [6] T. Tamrat and D. R. Yesudass, "A review on anticancer activity of some plant-derived compounds and their mode of action," *Natural Products Chemistry and Research*, vol. 6, no. 4, 2018.
- [7] R. Srinivasan, D. Natarajan, and M. S. Shivakumar, "Chemical composition and larvicidal activity of *Elaeagnus indica* Serrett. (Elaeagnaceae) plant leaf extracts against dengue and malaria vectors," *International Journal of Mosquito Research*, vol. 1, no. 4, pp. 66–71, 2014.
- [8] R. Srinivasan, D. Natarajan, and M. S. Shivakumar, "Antimicrobial and GC-MS analysis of *Mecycylon edule* leaf

- extracts,” *International Journal of Current Pharmaceutical Review and Research*, vol. 5, no. 1, pp. 1–13, 2014.
- [9] S. Babu, S. Ellango, and N. Dora, “Free radical scavenging activity of leaves of *Memecylon edule* Roxb,” *Research Journal in Pharmacognosy and Phytochemistry*, vol. 1, pp. 2109–2112, 2009.
- [10] T. Elavazhagan and D. K. Arunachalam, “Phytochemical and antibacterial studies of seed extracts of *Memecylon edule*,” *International Journal of Engineering, Science and Technology*, vol. 2, no. 4, pp. 498–503, 2010.
- [11] S. Nualkaew, K. Rattanamane, S. Thongpraditchote, Y. Wongkrajang, and A. Nahrstedt, “Anti-inflammatory, analgesic and wound healing activities of the leaves of *Memecylon edule* Roxb,” *Journal of Ethnopharmacology*, vol. 121, no. 2, pp. 278–281, 2009.
- [12] K. Palaniselvam, R. S. D. Paul Raj, N. Govindan et al., “Isolation, identification of secondary metabolites and antibacterial property of *Memecylon edule* leaves extract,” *Journal of Life Sciences*, vol. 1, no. 2, pp. 75–79, 2012.
- [13] N. RameshKannan, A. A. J., Nayagam, S. Gurunagara et al., “Photochemical screening from *Elaeagnus indica* activity against human pathogens and cancer cells,” *Advances in Biological Research*, vol. 7, no. 3, pp. 95–103, 2013.
- [14] M. S. Shivakumar, R. Srinivasan, and D. Natarajan, “Larvicidal potential of some Indian medicinal plant extracts against *Aedes aegypti* (L.),” *Asian Journal of Phytomedicine and Clinical Research*, vol. 6, no. 3, pp. 77–80, 2013.
- [15] R. Srinivasan, D. Natarajan, M. S. Shivakumar, T. Vinuchakkaravarthy, and D. Velmurugan, “Bioassay guided isolation of mosquito larvicidal compound from acetone leaf extract of *Elaeagnus indica* Servett Bull and its in-silico study,” *Industrial Crops and Products*, vol. 76, pp. 394–401, 2015.
- [16] R. Srinivasan, D. Natarajan, M. Subramaniam Shivakumar, and N. Nagamurugan, “Isolation of fisetin from *Elaeagnus indica* Servett. Bull. (*Elaeagnaceae*) with antioxidant and antiproliferative activity,” *Free Radicals and Antioxidants*, vol. 6, no. 2, pp. 145–150, 2016.
- [17] R. Srinivasan, D. Natarajan, and M. S. Shivakumar, “Spectral characterization and antibacterial activity of an isolated compound from *Memecylon edule* leaves,” *Journal of Photochemistry and Photobiology B: Biology*, vol. 168, pp. 20–24, 2017.
- [18] L. López-Hortas, P. Pérez-Larrán, M. J. González-Muñoz, E. Falqué, and H. Domínguez, “Recent developments on the extraction and application of ursolic acid—a review,” *Food Research International*, vol. 103, pp. 130–149, 2018.
- [19] X. M. Feng and X. L. Su, “Anticancer effect of ursolic acid via mitochondria-dependent pathways (review),” *Oncology Letters*, vol. 17, pp. 4761–4767, 2019.
- [20] E. W. C. Chan, C. Y. Soon, J. B. L. Tan, S. K. Wong, and Y. W. Hui, “Ursolic acid: an overview on its cytotoxic activities against breast and colorectal cancer cells,” *Journal of Integrative Medicine*, vol. 17, no. 3, pp. 155–160, 2019.
- [21] J. Iqbal, B. A. Abbasi, R. Ahmad et al., “Ursolic acid a promising candidate in the therapeutics of breast cancer: current status and future implications,” *Biomedicine & Pharmacotherapy*, vol. 108, pp. 752–756, 2018.
- [22] Y.-L. Chew, J.-K. Goh, and Y.-Y. Lim, “Assessment of *in vitro* antioxidant capacity and polyphenolic composition of selected medicinal herbs from Leguminosae family in peninsular Malaysia,” *Food Chemistry*, vol. 116, no. 1, pp. 13–18, 2009.
- [23] B. Halliwell, J. M. C. Gutteridge, and C. E. Cross, “Free radicals, antioxidants and human disease: where are we now?,” *Journal of Laboratory and Clinical Medicine*, vol. 119, pp. 598–620, 1992.
- [24] F. Liu, V. E. C. Ooi, and S. T. Chang, “Free radical scavenging activities of mushroom polysaccharide extracts,” *Life Sciences*, vol. 60, no. 10, pp. 763–771, 1997.
- [25] G.-C. Yen and H.-Y. Chen, “Antioxidant activity of various tea extracts in relation to their antimutagenicity,” *Journal of Agricultural and Food Chemistry*, vol. 43, no. 1, pp. 27–32, 1995.
- [26] Glide, *Glide, Version 5.5*, Schrödinger, LLC, New York, NY, USA, 2009.
- [27] J. S. Lee, S. Ramalingam, I. G. Jo et al., “Comparative study of the physicochemical, nutritional, and antioxidant properties of some commercial refined and non-centrifugal sugars,” *Food Research International*, vol. 109, pp. 614–625, 2018.
- [28] S. Walch, G. W. Dirk Lachenmeier, T. Kuballa et al., “Holistic control of herbal teas and tinctures based on sage (*Salvia officinalis* L.) for compounds with beneficial and adverse effects using NMR spectroscopy,” *Analytical Chemistry Insights*, vol. 7, pp. 1–12, 2012.
- [29] A. Kadri, I. B. Chobba, and Z. Zarai, “Chemical constituents and antioxidant activity of the essential oil from aerial parts of *Artemisia herba-alba* grown in Tunisian semi-arid region,” *African Journal of Biotechnology*, vol. 10, no. 15, pp. 2923–2929, 2011.
- [30] K. Murugan, D. P. Pradeep, and V. G. Meenu Krishnan, “Comparison of essential oils composition and antioxidant activities of *Artemisia japonica* Thunb. and *A. Nilagirica* (Clarke) pamp,” *Indo American Journal of Pharmaceutical Research*, vol. 4, no. 2, pp. 832–837, 2014.
- [31] K. Msaada, N. Salem, O. Bachrouh et al., “Chemical composition and antioxidant and antimicrobial activities of wormwood (*Artemisia absinthium* L.) essential oils and phenolics,” *Journal of Chemistry*, vol. 2015, Article ID 804658, 12 pages, 2015.
- [32] H. Mighri, H. Hajlaoui, A. Akrouf, H. Najjaa, and M. Neffati, “Antimicrobial and antioxidant activities of *Artemisia herba-alba* essential oil cultivated in Tunisian arid zone,” *Comptes Rendus Chimie*, vol. 13, no. 3, pp. 380–386, 2010.
- [33] G. G. P. Nascimento, L. G. Telma Lemos, M. C. Ayla Bizerra et al., “Antibacterial and antioxidant activities of ursolic acid and derivatives,” *Molecules*, vol. 19, no. 1, pp. 1317–1327, 2014.
- [34] L. Novotny, A. Vachalkova, and D. Biggs, “Ursolic acid: an anti-tumorigenic and chemopreventive activity mini review,” *Neoplasma*, vol. 48, pp. 241–246, 2001.
- [35] M. Kondo, “*Phytochemical studies of extracts from Cranberry (Vaccinium macrocarpon) with anti-cancer, anti-fungal and cardioprotective properties*,” M.S. thesis, University of Massachusetts Amherst, Dartmouth, MA, USA, 2006.
- [36] C. C. Neto, “Cranberry and its phytochemicals: a review of *in vitro* anticancer studies,” *The Journal of Nutrition*, vol. 137, no. 1, pp. 186S–193S, 2007.
- [37] D. Andersson, J. J. Liu, A. Nilsson et al., “Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase,” *Anticancer Research*, vol. 23, pp. 3317–3322, 2003.
- [38] H. Chen, Y. Gao, A. Wang, X. Zhou, Y. Zheng, and J. Zhou, “Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents,” *European Journal of Medicinal Chemistry*, vol. 92, pp. 648–655, 2015.
- [39] J. H. Baek, Y. S. Lee, C. M. Kang et al., “Intracellular Ca²⁺ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells,” *International Journal of Cancer*, vol. 73, no. 5, pp. 725–728, 1997.

- [40] M. Wang, J. Li, Y. Shao, and T. Huang, "Anti-oxidative and cytotoxic components of high bush blueberry (*Vaccinium corymbosum* L.)," in *Phytochemicals and Phytopharmaceuticals*, pp. 271–277, AOCS Press, Champaign, IL, USA, 2000.
- [41] D. Es-saady, A. Simon, and C. J. Vignoles, "MCF-7 cell cycle arrested at G1 through ursolic acid and increased reduction of tetrazolium salts," *Anticancer Research*, vol. 16, pp. 481–486, 1996.
- [42] S. Leng, Y. Hao, and D. Du, "Ursolic acid promotes cancer cell death by inducing Atg5-dependent autophagy," *International Journal of Cancer*, vol. 133, no. 12, pp. 2781–2790, 2013.
- [43] R. Biswas, S. K. Mandal, S. Dutta et al., "Thujone-rich fraction of *Thuja occidentalis* demonstrates major anticancer potentials: evidences from in vitro studies on A375 cells," *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 568148, 16 pages, 2011.
- [44] G. Zolotovitch, S. Stoichev, K. Nachev et al., "Cytotoxic effect of phenols, phenol ethers furan derivatives, and oxides isolated from essential oils," *Comptes Rendus de l'Academie Bulgare des Sciences*, vol. 20, p. 1341, 1967.
- [45] J. L. Delgado, C.-M. Hsieh, N.-L. Chan, and H. Hiasa, "Topoisomerases as anticancer targets," *Biochemical Journal*, vol. 475, no. 2, pp. 373–398, 2019.
- [46] J. L. Nitiss, "Targeting DNA topoisomerase II in cancer chemotherapy," *Nature Reviews Cancer*, vol. 9, no. 5, pp. 338–350, 2009.
- [47] S. Baikar and N. Malpathak, "Secondary metabolites as DNA topoisomerase inhibitors: a new era towards designing of anticancer drugs," *Pharmacognosy Reviews*, vol. 4, no. 7, pp. 12–26, 2010.
- [48] W. N. Setzer, "Non-intercalative triterpenoid inhibitors of topoisomerase II: a molecular docking study," *The Open Bioactive Compounds Journal*, vol. 1, pp. 13–17, 2008.
- [49] Y. Mizushima, A. Iida, K. Ohta, F. Sugawara, and K. Sakaguchi, "Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase," *Biochemical Journal*, vol. 350, no. 3, pp. 757–763, 2000.
- [50] D.-K. Kim, J. H. Baek, C.-M. Kang et al., "Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication," *International Journal of Cancer*, vol. 87, no. 5, pp. 629–636, 2000.
- [51] B. Chhetri, N. Dosoky, and W. Setzer, "Cytotoxic norhopene triterpenoids from the bark of *Exothea paniculata* from Abaco Island, Bahamas," *Planta Medica Letters*, vol. 2, no. 1, pp. e73–e77, 2015.